BenzingaOctober 15, 2026 at 4:38 AM NY12 Days Ago
Actinium Pharmaceuticals To Present Early Phase 1 Clinical Data For ATNM-400 In Metastatic Prostate Cancer At EANM 2026
Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation of
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
